- Portola Pharmaceuticals (NASDAQ:PTLA -10%) enters into a second clinical collaboration agreement with Daiichi Sankyo to study andexanet alfa, PTLA's investigational Factor Xa inhibitor antidote in a Phase 3 clinical trial with Daiichi's Factor Xa inhibitor edoxaban. Portola's first collaboration agreement covered a Phase 2 proof-of-concept study. The Phase 3 trial is expected to commence in 2015.
- Under the terms of the agreement, Portola will receive an upfront payment as well as development- and regulatory-related milestone payments. It retains full worldwide commercial rights to andexanet alfa for which it is pursuing an Accelerated Approval pathway.
Portola inks collaboration deal with Daiichi Sankyo
Recommended For You
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
PTLA | - | - |
Portola Pharmaceuticals, Inc. |